Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

Melinda L. Telli,Jennifer K. Litton,Joseph Thaddeus Beck,Jason M. Jones,Jay Andersen,Lida A. Mina,Raymond Brig,Michael A. Danso,Yuan Yuan,William Fraser Symmans,Antonello Abbattista,Kay Noonan,Marielena Mata,Douglas Laird,Joanne L. Blum

Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

2021

Melinda L. Telli
Jennifer K. Litton
Joseph Thaddeus Beck
Jason M. Jones
Jay Andersen
Lida A. Mina
Raymond Brig
Michael A. Danso
Yuan Yuan
William Fraser Symmans
Antonello Abbattista
Kay Noonan
Marielena Mata
Douglas Laird
Joanne L. Blum

554Background: TALA is a poly(ADP-ribose) polymerase inhibitor approved as monotherapy for adult pts with gBRCA1/2-mutated HER2-negative locally advanced/metastatic BC. We report biomarker analyses...

Keywords:

Internal medicine
Medicine
Zygosity
Talazoparib
Oncology
Biomarker (medicine)
Phases of clinical research
Germline
in patient
Mutation
Breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations